f Epicardial Adipose Tissue Modulation: A New Horizon for Sodium-glucose Cotransporter 2 Inhibitors

References

1. TheofilisP. OikonomouE. K. VlachakisP. Sodium-glucose cotransporter 2 inhibitors and changes in epicardial adipose tissue: A systematic literature review and meta-analysis.Curr Vasc Pharmacol in press2025 39819408
   [Google Scholar]
2. MuzurovićE.M. VujoševićS. MikhailidisD.P. Can we decrease epicardial and pericardial fat in patients with diabetes?J. Cardiovasc. Pharmacol. Ther.202126541543610.1177/10742484211006997 33844605
   [Google Scholar]
3. MuzurovićE. CojićM. StankovićZ. JanežA. Epicardial adipocyte-derived TNF-α modulates local inflammation in patients with advanced coronary artery disease.Curr. Vasc. Pharmacol.2022201949510.2174/157016112001211228145754 35040396
   [Google Scholar]
4. KatsikiN. RizzoM. MikhailidisD.P. Epicardial, peripancreatic and other “orthotopic” excessive fat deposition in south Asians and Europeans: Are differences clinically relevant?J. Diabetes Complications202337410841910.1016/j.jdiacomp.2023.108419 36871315
   [Google Scholar]
5. NaukkarinenJ. HeinonenS. HakkarainenA. Characterising metabolically healthy obesity in weight-discordant monozygotic twins.Diabetologia201457116717610.1007/s00125‑013‑3066‑y 24100782
   [Google Scholar]
6. IacobellisG. Epicardial fat links obesity to cardiovascular diseases.Prog. Cardiovasc. Dis.202378273310.1016/j.pcad.2023.04.006 37105279
   [Google Scholar]
7. WangW. GaoY. WangJ. Prognostic value of epicardial adipose tissue in heart failure with mid‐range and preserved ejection fraction: A multicenter study.J. Am. Heart Assoc.20241324e03678910.1161/JAHA.124.036789 39673347
   [Google Scholar]
8. MyasoedovaV.A. ParisiV. MoschettaD. Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: A systematic review and meta-analysis.Cardiovasc. Diabetol.20232212310.1186/s12933‑023‑01738‑2 36721184
   [Google Scholar]
9. BorozanS. VujoševićS. MikhailidisD.P. MuzurovićE. Metabolic dysfunction-associated steatohepatitis and cardiovascular disease prevention: Is resmetirom useful?Curr. Vasc. Pharmacol.2024Epub ahead of print10.2174/0115701611340703240809044916 39129278
   [Google Scholar]
10. KokkorakisM. MuzurovićE. VolčanšekŠ. Steatotic liver disease: Pathophysiology and emerging pharmacotherapies.Pharmacol. Rev.202476345449910.1124/pharmrev.123.001087 38697855
    [Google Scholar]
11. TarsitanoM.G. PandozziC. MuscogiuriG. Epicardial adipose tissue: A novel potential imaging marker of comorbidities caused by chronic inflammation.Nutrients20221414292610.3390/nu14142926 35889883
    [Google Scholar]
12. KatsikiN. MikhailidisD.P. Pericoronary adipose tissue in atherosclerosis: Current and future perspectives.Angiology20237415610.1177/00033197221127597 36113124
    [Google Scholar]
13. KatsikiN. AthyrosV.G. MikhailidisD.P. Abnormal peri-organ or intra-organ fat (APIFat) deposition: An underestimated predictor of vascular risk?Curr. Vasc. Pharmacol.201614543244110.2174/1570161114666160722112738 27456108
    [Google Scholar]
14. KoningsL.A.M. Miguelañez-MatuteL. BoerenA.M.P. Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review.Eur. J. Clin. Invest.2025e7000310.1111/eci.70003 39937036
    [Google Scholar]
15. MuzurovićE. PengC.C.H. BelangerM.J. SanoudouD. MikhailidisD.P. MantzorosC.S. Nonalcoholic fatty liver disease and cardiovascular disease: A review of shared cardiometabolic risk factors.Hypertension20227971319132610.1161/HYPERTENSIONAHA.122.17982 35465684
    [Google Scholar]